Novartis' TREM2 drug fails Phase 2 ALS trial
Medical News||1 分钟阅读
核心洞察
Novartis has discontinued development of a Phase 2 treatment candidate for amyotrophic lateral sclerosis (搜索), according to Endpoints News.
The Swiss pharmaceutical company is ending work on the TREM2 (搜索)-directed program following the failed mid-stage ALS trial.
The decision removes a TREM2 (搜索)-targeting asset from the ALS pipeline, where few disease-modifying options currently exist.
Novartis has scrapped development of a Phase 2 treatment candidate for amyotrophic lateral sclerosis (搜索), Endpoints News has learned. The Swiss pharma giant is ending work on the program, which targeted TREM2 (搜索).
The decision follows a failed Phase 2 trial in ALS, removing a TREM2 (搜索)-directed asset from the company's clinical pipeline.